Table 1. Clinicopathological findings of patients with ypT0 and ypTis in the breast after neoadjuvant chemotherapy.
| Parameters | ypT0 (n = 67, %) | ypTis (n = 50, %) | P-value |
|---|---|---|---|
| Age (year) | |||
| Mean ± SD | 49.6 ± 10.4 | 49.1 ± 8.7 | 0.772a |
| ≤40 | 13 (68.4) | 6 (31.6) | 0.283 |
| >40 | 54 (55.1) | 44 (44.9) | |
| Menopause | |||
| Premenopause | 35 (56.5) | 27 (43.5) | 0.850 |
| Postmenopause | 32 (58.2) | 23 (41.8) | |
| BMI (kg/m2) | |||
| <25 | 46 (57.5) | 34 (42.5) | 0.940 |
| ≥25 | 21 (56.8) | 16 (43.2) | |
| Clinical tumor stage at presentation | |||
| T1 | 26 (66.7) | 13 (33.3) | 0.340 |
| T2 | 34 (53.1) | 30 (46.9) | |
| T3-4 | 7 (50.0) | 7 (50.0) | |
| Node status at presentation | |||
| Negative | 9 (64.3) | 5 (35.7) | 0.571 |
| Positive | 58 (56.3) | 45 (43.7) | |
| Regimens of NCT | |||
| AC followed by T | 49 (73.1) | 42 (84.0) | 0.070 |
| AC followed by T+TS1 | 6 (9.0) | 6 (12.0) | |
| Others | 12 (17.9) | 2 (4.0) | |
| Pathologic node status after NCT | |||
| ypN0 | 58 (60.4) | 38 (39.6) | 0.141 |
| ypN1-3 | 9 (42.9) | 12 (57.1) | |
| Histologic grade | |||
| I/II | 36 (56.2) | 28 (43.8) | 0.807 |
| III | 31 (58.5) | 22 (41.5) | |
| ER | |||
| Negative | 43 (65.2) | 23 (34.8) | 0.050 |
| Positive | 24 (47.1) | 27 (52.9) | |
| PR | |||
| Negative | 56 (62.2) | 34 (37.8) | 0.048 |
| Positive | 11 (40.7) | 16 (59.3) | |
| HER2 | |||
| Negative | 50 (68.5) | 23 (31.5) | 0.002 |
| Positive | 17 (38.6) | 27 (61.4) | |
| Breast cancer subtype | |||
| HRs+/HER2- | 17 (51.5) | 16 (48.5) | 0.001 |
| HRs+/HER2+ | 7 (36.8) | 12 (63.2) | |
| HRs-/HER2+ | 10 (40.0) | 15 (60.0) | |
| HRs-/HER2- | 33 (82.5) | 7 (17.5) | |
| Ki-67 before NCT (n = 105) | |||
| ≤15% | 17 (45.9) | 20 (54.1) | 0.119 |
| >15% | 42 (61.8) | 26 (38.2) | |
| Surgery | |||
| Breast-conservation | 46 (68.7) | 21 (31.3) | 0.004 |
| Total mastectomy | 21 (42.0) | 29 (58.0) |
SD, standard deviation; BMI, body mass index; NCT, neoadjuvant chemotherapy; AC, anthracycline plus cyclophosphamide; T, docetaxel; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; HRs, hormone receptors.
aIndependent samples t-test.